Incretin-Based Drugs Market By Drug Class (GLP-1 Receptor Agonists, Dual GIP/GLP-1 Receptor Agonists, DPP-4 Inhibitors, Oral Small-Molecule GLP-1 Agonists, Triple-Receptor Agonists, Dual GLP-1/Glucagon Agonists, Amylin/GLP-1 and Other Next-Generation Incretin Agents), By Application (Type 2 Diabetes, Obesity and Weight Management, Cardiovascular Risk Reduction, Obstructive Sleep Apnea, MASH and Other Cardiometabolic Disorders), By Route of Administration (Injectable, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Incretin-Based Drugs Market: From Glucose Control to Cardiometabolic Platforms Expanding Patient Base Driving Prescription Growth

The Global Incretin-Based Drugs Market was valued at USD 86.80 billion in 2025 and is projected to reach USD 201.80 billion by 2032, expanding at a CAGR of 12.8% during 2026–2032, according to Strategic Market Research.

 

Incretin-based treatment relies on selective GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, dual GIP/GLP-1 receptor agonists such as tirzepatide, and DPP-4 inhibitors such as sitagliptin, linagliptin, and saxagliptin. The next wave of competition includes oral GLP-1 medicines, triple-receptor agonists, GLP-1/glucagon combinations, and amylin- or GIP-based combinations intended to improve weight reduction, treatment convenience, and long-term continuation.

 

The incretin-based drugs market has shifted from a relatively focused type 2 diabetes category into a broader cardiometabolic treatment platform. Injectable and oral GLP-1 therapies now compete on weight reduction, cardiovascular risk, and organ-related outcomes, while DPP-4 inhibitors remain established oral glucose-lowering options with a more modest clinical and commercial profile.

 

The addressable population extends across diabetes and obesity. The World Health Organization estimates that 830 million people were living with diabetes in 2022, up from 200 million in 1990, while 59% of adults aged 30 and older with diabetes were not taking medication. WHO also reports that obesity affects more than 1 billion people worldwide.

 

The United States shows how quickly that funnel can convert into utilization. In 2024, 26.5% of U.S. adults with diagnosed diabetes—approximately 6.9 million people—reported using GLP-1 injectables. Utilization reached 32.4% among adults with both diagnosed diabetes and obesity, making overlapping metabolic conditions one of the highest-value treatment pools.

 

Approved Therapies and Next-Generation Agents Are Redrawing Competition

Approved GLP-1 receptor agonists include semaglutide products such as Ozempic, Wegovy, and Rybelsus, as well as liraglutide, dulaglutide, exenatide, and lixisenatide. Their contribution to market revenue continues to rise as these therapies move beyond glucose control into obesity and related cardiovascular conditions. The potential treatment population is substantial. When approving Zepbound for chronic weight management, the US FDA noted that approximately 70% of American adults were living with overweight or obesity, many of whom also had at least one weight-related health condition.

Tirzepatide, sold as Mounjaro and Zepbound, forms the approved dual GIP/GLP-1 segment. Its weight-loss performance has raised expectations across the incretin market and placed greater competitive pressure on single-receptor therapies. Zepbound’s initial approval was supported by two randomized studies in which 2,519 patients received tirzepatide and 958 received a placebo for 72 weeks. At the highest approved dose, adults without diabetes lost an average of 18% of their body weight, while those with type 2 diabetes achieved an average reduction of 12%.

DPP-4 inhibitors, including sitagliptin, saxagliptin, linagliptin, and alogliptin, remain widely used oral treatments for type 2 diabetes. However, their weight-neutral profile, limited use beyond glucose management, and increasing generic availability leave the category more exposed to price competition. The arrival of oral GLP-1 medicines is likely to intensify this pressure by offering tablet-based treatment with more meaningful weight-management benefits.

Oral therapies are becoming a more important part of the competitive landscape. The FDA approved Foundayo, orforglipron, for chronic weight management in April 2026. As a non-peptide oral GLP-1 receptor agonist, the product removes the injection barrier and could attract patients who delay or reject injectable treatment. Its tablet format also creates direct competition for both conventional oral diabetes drugs and established injectable GLP-1 brands. The market gained another formulation option in March 2026 when the FDA approved Wegovy HD, a higher 7.2 mg dose of semaglutide, for selected adults requiring chronic weight management.

The next stage of competition is being shaped by therapies that act on several metabolic pathways. Retatrutide, an investigational GLP-1, GIP, and glucagon triple-receptor agonist, reported positive Phase 3 obesity results in 2026. In the TRIUMPH-1 trial, the highest dose produced an average weight reduction of 28.3% after 80 weeks, although the therapy remains unapproved. Its broader Phase 3 program includes a study of patients with severe obesity and established cardiovascular disease lasting approximately 113 weeks.

CagriSema combines semaglutide with the amylin analogue cagrilintide and is being evaluated in Phase 3 programs for obesity and type 2 diabetes. Its development program includes long-term obesity studies and a direct comparison with tirzepatide. MariTide, which combines GLP-1 receptor activation with GIP receptor inhibition, has also entered Phase 3 development. Amgen is positioning less-frequent administration as a point of differentiation from the once-weekly dosing used by several established products.

Dual GLP-1 and glucagon therapies are progressing differently across regional markets. Mazdutide received Chinese approval for chronic weight management in June 2025 and for glycemic control in adults with type 2 diabetes in September 2025. It should therefore be treated as an approved next-generation product in China rather than as a pipeline-only asset.

Pemvidutide remains investigational, with its development strategy increasingly centred on metabolic dysfunction-associated steatohepatitis and other serious liver diseases. Altimmune plans to advance the therapy into a registrational Phase 3 MASH study during the second half of 2026. Across the wider pipeline, competitive performance will depend not only on reported weight loss but also on administration route, dosing frequency, treatment persistence, indication breadth, manufacturing capacity, and reimbursement access.

 

GLP-1 and Dual Agonists Are Reshaping the Value of Diabetes Care

Selective GLP-1 receptor agonists established the market by delivering both glucose control and meaningful weight reduction. The introduction of dual GIP/GLP-1 therapy raised the clinical performance standard further. In the pivotal obesity trials reviewed by the FDA, the highest approved dose of tirzepatide produced average weight loss of 18% in adults without diabetes and 12% in those with type 2 diabetes. These outcomes have shifted treatment decisions beyond blood-glucose control toward broader weight-management and cardiometabolic benefits.

DPP-4 inhibitors continue to serve patients who require an oral, weight-neutral treatment for type 2 diabetes. However, their competitive position is becoming increasingly defensive as physicians and payers place greater emphasis on weight loss and wider cardiometabolic outcomes. The category is expected to retain prescription volume among older adults, patients unable to tolerate stronger incretin therapies, and health systems that favour established oral medicines. Even so, its share of total market revenue is likely to decline as higher-value GLP-1 and dual-receptor therapies gain wider adoption.

 

Label Expansion Is Opening New Budgets and Prescriber Groups

Regulatory expansion is converting leading incretin medicines into multi-indication franchises. In March 2024, the FDA approved Wegovy to reduce cardiovascular death, heart attack, and stroke risk in adults with cardiovascular disease and overweight or obesity. In December 2024, Zepbound became the first FDA-approved medicine for moderate-to-severe obstructive sleep apnea in adults with obesity. Wegovy received an additional U.S. approval in August 2025 for noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, with moderate-to-advanced fibrosis.

Treatment use is no longer driven only by endocrinologists and obesity specialists; cardiologists, sleep specialists, hepatologists, and primary-care physicians can now influence prescribing across related conditions. The expanded indication base also strengthens the case for payer coverage, enabling manufacturers to seek reimbursement through cardiovascular, sleep-disorder, and liver-disease pathways rather than relying solely on weight-management benefits.

Oral products can attract patients who are reluctant to use injections while reducing manufacturers’ dependence on injection-device capacity. Additional dosing options allow established brands to address a wider range of treatment needs, extend product lifecycles, and defend market share as competition increases.

 

Commercial Leadership Now Depends on Scale as Much as Clinical Evidence

Company filings highlight the high level of revenue concentration within the market. Eli Lilly reported 2025 revenue of USD 22.97 billion from Mounjaro and USD 13.54 billion from Zepbound, representing year-on-year growth of 99% and 175%, respectively. Combined, the two tirzepatide brands generated approximately USD 36.5 billion and accounted for nearly 56% of Lilly’s total annual revenue.

Based on an estimated global incretin-based drugs market size of USD 86.80 billion in 2025, Mounjaro and Zepbound collectively accounted for an estimated market share of approximately 42.1%. Mounjaro alone contributed around 26.5% of total global market revenue and 62.9% of the tirzepatide franchise, while Zepbound represented approximately 15.6% of the overall market and 37.1% of franchise revenue.

Novo Nordisk reported 2025 Wegovy sales of DKK 79.11 billion, representing growth of 41% at constant exchange rates. Total obesity-care sales reached DKK 82.35 billion, indicating that Wegovy generated an analyst-calculated 96.1% of the company’s obesity-care revenue.

Victoza, meanwhile, recorded a 43% decline at constant exchange rates. The contrasting performance shows that market growth is increasingly concentrated in longer-acting therapies that deliver stronger clinical outcomes, rather than being distributed evenly across all products in the incretin-based drug class.

Manufacturing capacity remains a competitive barrier. Novo Nordisk spent DKK 60.1 billion on property, plant, and equipment in 2025, primarily to expand active-ingredient and fill-finish capacity for injectable and oral products. Suppliers that maintain starter-dose availability and uninterrupted refills protect both patient persistence and recurring revenue.

 

Reimbursement Is Expanding, but Access Remains Managed

Public payers are beginning to treat incretin access as a structured chronic-care decision rather than a broad consumer weight-loss benefit. WHO added semaglutide, dulaglutide, liraglutide, and tirzepatide to its 2025 Essential Medicines List for adults with type 2 diabetes who also have established cardiovascular disease, chronic kidney disease, or obesity. WHO’s first obesity guideline, released in December 2025, conditionally recommended GLP-1 therapies as long-term treatment for adults with obesity while emphasizing equitable access and health-system readiness.

In the United States, the Medicare GLP-1 Bridge launched on July 1, 2026, offering eligible beneficiaries selected weight-management medicines for a USD 50 monthly copayment through December 31, 2027. The program creates a publicly funded access channel, although eligibility rules, prior authorization, and indication boundaries will control prescription volume.

England illustrates a slower, capacity-led model. NHS England plans to identify approximately 220,000 eligible people for tirzepatide during the first three years of a phased 12-year rollout. The timetable reflects medicine expenditure, primary-care capacity, patient prioritization, workforce training, and the need to build weight-management services.

 

Persistence Determines How Much Clinical Demand Becomes Revenue

High initiation does not guarantee durable market value. A 2025 JAMA Network Open study of 125,474 U.S. adults with overweight or obesity found that 46.5% of patients with type 2 diabetes and 64.8% of those without diabetes discontinued GLP-1 therapy within one year. Cost, adverse effects, supply interruptions, and unmet expectations can therefore reduce annual revenue per patient even when prescription starts remain strong.

Gastrointestinal effects—including nausea, vomiting, constipation, and diarrhea—remain the most common tolerability concerns for GLP-1 therapies. DPP-4 inhibitors generally have a milder gastrointestinal profile, preserving a role for them among patients unable or unwilling to sustain stronger incretin therapy. Patient support, reliable supply, and refill continuity are commercial necessities because discontinuation weakens both outcomes and recurring sales.

The unapproved and compounded channel adds another risk. The FDA has warned about dosing errors, fraudulent labels, and misleading promotion involving unapproved semaglutide and tirzepatide products. As branded supply stabilizes, enforcement may redirect demand toward approved products, but it also increases scrutiny of telehealth prescribing, pharmacy sourcing, advertising, and dosing practices.

 

Regional Growth Is Broadening Beyond the U.S. Launch Model

North America remains the principal revenue center because of its high diagnosed prevalence, intensive prescribing, commercial insurance, and self-pay channels. Europe is expanding through national reimbursement decisions and controlled public-health rollouts. Asia-Pacific offers substantial volume potential but will develop through country-specific pricing, local approvals, supply availability, and public coverage rather than a single regional adoption curve.

Company results show this geographic broadening. Novo Nordisk’s 2025 obesity-care sales reached DKK 51.28 billion in U.S. operations and DKK 31.06 billion in international operations, equal to approximately 62.3% and 37.7% of its global obesity-care revenue, respectively. EUCAN generated DKK 16.83 billion, or approximately 20.4% of the company’s obesity-care sales, and grew 62% at constant exchange rates. Asia-Pacific contributed DKK 6.08 billion, or about 7.4%, while expanding 122% at constant exchange rates. Emerging Markets generated DKK 7.34 billion, equivalent to 8.9% of obesity-care revenue, with 59% growth, while China contributed DKK 824 million and recorded 182% growth from a smaller launch base. These are company-level figures rather than total-market estimates, but they demonstrate that incretin revenue growth is no longer confined to the United States.

 

Incretin-Based Drugs Market: Competition Is Shifting from Maximum Efficacy to Sustainable Access

The next stage of the incretin-based drugs market will be decided by the number of covered patients, net price after rebates, persistence beyond the first year, manufacturing reliability, oral versus injectable preference, additional indications, and the ability to demonstrate value against downstream cardiometabolic costs.

Selective GLP-1 agonists and dual agonists will remain the main growth engines, while oral GLP-1 products and multi-receptor candidates broaden the addressable population and challenge both injectable brands and DPP-4 inhibitors. The overall market’s projected 12.8% CAGR through 2032 reflects this shift toward premium multi-indication therapies, although segment performance will vary by reimbursement, regional access, product format, and patient persistence. The strongest suppliers will be those that combine differentiated outcomes with scalable production, payer access, and long-term patient continuity rather than relying on initial prescription demand alone.

 

Incretin-Based Drugs Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 86.80 Billion
Revenue Forecast in 2032	USD 201.80 Billion
Overall Growth Rate	CAGR of 12.8% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million/Billion, CAGR (2026–2032)
Segmentation	By Drug Class, By Application, By Route of Administration, By Distribution Channel, By Geography
By Drug Class	GLP-1 Receptor Agonists, Dual GIP/GLP-1 Receptor Agonists, DPP-4 Inhibitors, Oral Small-Molecule GLP-1 Agonists, Triple-Receptor Agonists, Dual GLP-1/Glucagon Agonists, Amylin/GLP-1 and Other Next-Generation Incretin Agents
By Application	Type 2 Diabetes, Obesity and Weight Management, Cardiovascular Risk Reduction, Obstructive Sleep Apnea, MASH and Other Cardiometabolic Disorders
By Route of Administration	Injectable, Oral
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising diabetes and obesity prevalence, expanding cardiometabolic indications, increasing GLP-1 and dual-agonist adoption, development of oral and multi-receptor therapies, improving reimbursement access and growing demand for effective weight-management medicines
Customization Option	Available upon request